WELCOME > News > NEWS

NEWS

NEWS PANAGENE's Colorectal Cancer-Related Mutation Test Kit, approved for Health Insurance Benefits

2017-09-28 | View 10607

 

PANAGENE's Colorectal Cancer-Related Mutation Test Kit, approved for Health Insurance Benefits 

 

PANAGENE, PNA (Peptide Nucleic Acid)-based diagnostics company, has announced that its 'PNAClamp NRAS Mutation Detection Kit', which is used to prescribe a targeted therapy and treatment for colorectal cancer patients, was approved as a product covered by health insurance benefits. The health insurance benefits using PNAClamp NRAS Mutation Detection Kit will be applied from October.

 

The PNAClamp™ NRAS Mutation Detection Kit (PNA) is a mutation test product that can help decide on targeted therapy for colon cancer, such as Merck's Erbitux, and it is expected that many colon cancer patients can benefit through this approval.

 

 

For the original article, please click the following link.

http://news.mk.co.kr/newsRead.php?year=2017&no=645071

 

 

- PANAGENE, Inc. - 

 

 

List